Terminated PHASE2 INTERVENTIONAL 2-arm NCT00702221

Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension

A Randomised, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Subjects With Mild to Moderate Hypertension

Sponsor: BTG International Inc.

Conditions Cardiovascular Disease Hypertension

Interventions Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant CoVaccine HT™ adjuvant

Updated 8 times since 2017 Last updated: Jun 20, 2016 Started: Jun 30, 2008 Primary completion: Jun 30, 2009 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Dose limiting adverse effects

Other terminated trials from BTG International Inc.

More terminations from BTG International Inc.

Other Cardiovascular Disease trials with similar outcome

Browse all Cardiovascular Disease trials

Listed as NCT00702221, this PHASE2 trial focuses on Cardiovascular Disease and Hypertension and remains terminated or withdrawn. Sponsored by BTG International Inc., it has been updated 8 times since 2008, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BTG International Inc.
Encorium

Data source: BTG International Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Blackpool, United Kingdom , Chesterfield, United Kingdom , Fowey, United Kingdom , Inkberrow, United Kingdom , Manchester, United Kingdom , Penzance, United Kingdom , Plymouth, United Kingdom , Royal Leamington Spa, United Kingdom , Saint Stephen, United Kingdom , Saltash, United Kingdom and 2 more locations